Inhibrx Biosciences Cancer Therapy Draws Big-Pharma Interest

Inhibrx Biosciences has attracted significant interest from major drugmakers including Merck & Co. and Ono Pharmaceutical for its experimental cancer therapy INBRX-106.

The treatment, which is being tested alone and in combination with Keytruda, a prescription immunotherapy, could be valued at over $8 billion if trials confirm its potential to boost treatment response rates.

Inhibrx Biosciences reported promising interim data from its Phase 1/2 trial for advanced colorectal cancer on Tuesday, showing a 20% response rate and a median progression-free survival of 5.5 months.

Retail traders on Stocktwits have turned 'extremely bullish' on the stock, with one user noting 'very strong data' from the Ozekibart trial, which also showed a manageable safety profile.